Matinas biopharma announces topline results from enhance-it study of lypdiso™ against vascepa®

– lypdiso ™ demonstrated a statistically significant 46% relative percent increase in epa change from baseline over vascepa ® –

MTNB Ratings Summary

MTNB Quant Ranking